for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sino Biopharmaceutical Limited

1177.HK

Latest Trade

11.38HKD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

4.53

 - 

12.24

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
11.38
Open
--
Volume
--
3M AVG Volume
1,112.31
Today's High
--
Today's Low
--
52 Week High
12.24
52 Week Low
4.53
Shares Out (MIL)
12,588.30
Market Cap (MIL)
141,996.10
Forward P/E
38.60
Dividend (Yield %)
0.71

Next Event

Q3 2019 Sino Biopharmaceutical Ltd Earnings Release

Latest Developments

More

Sino Biopharmaceutical Says Fosaprepitant Dimeglumine For Injection Obtains Approval For Drug Registration

Sino Biopharmaceutical Says Ticagrelor Tablet Obtained Provisional ANDA Approval From U.S. FDA

Sino Biopharmaceutical Says Azacitidine Obtained Approval For Drug Registration

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited is an investment holding company principally engaged in the medicine products business. The Company operates through three business segments. The Modernized Chinese Medicines and Chemical Medicines segment is engaged in the manufacture, sales and distribution of modernized Chinese medicine products and western medicine products. The Investment segment is engaged in long term investments. The Others segment is engaged in the provision of research and development activities and services to third parties, as well as related healthcare and hospital business. The Company is also involved in the property holding, the sales of health food, the manufacture and optometry of optical glasses, as well as the retail and wholesale of optical and auditory products through its subsidiaries.

Industry

Biotechnology & Drugs

Contact Info

Unit 09, 41F, Office Tower

Convention Plaza, No. 1 Harbour Road

Wanchai

+852.null.28029886

http://www.sinobiopharm.com

Executive Leadership

Y Y Tse

Executive Chairlady of the Board

Ping Tse

Chief Executive Officer, Executive Director

Cheung Ling Cheng

Executive Vice Chairlady of the Board

Minggang Wang

Vice Chairman of the Board and the General Manager of Qingdao Haier

Hui Cheng

Vice President - Finance, in charge of the finance department

Key Stats

1.83 mean rating - 24 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2016

13.5K

2017

14.8K

2018

20.9K

2019(E)

25.1K
EPS (CNY)

2016

0.147

2017

0.195

2018

0.230

2019(E)

0.262
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
4.25
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
10.92
LT Debt To Equity (MRQ)
8.23
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

China Resources Gas, Sino Biopharmaceutical to join Hang Seng China Enterprises Index

Hong Kong's stock index compiler said on Friday that China Resources Gas Group Ltd and Sino Biopharmaceutical Ltd have been selected to join the Hang Seng China Enterprises Index, while two companies will be removed.

BRIEF-Sino Biopharmaceutical Co Announces Acquisition of Sino Biopharm Beijing​ & Super Demand

* CO TO ACQUIRE SINO BIOPHARM BEIJING,WHICH OWNS 33.6% OF BEIJING TIDE, BY ISSUING 723.3 MILLION SHARES AT HK$12.73 PER ISSUE SHARE

BRIEF-Sino Biopharmaceutical Product Granted Drug Registration Approval By State FDA Of China​

* "TENOFOVIR DISOPROXIL FUMARATE TABLET" GRANTED DRUG REGISTRATION APPROVAL BY STATE FOOD AND DRUG ADMINISTRATION OF CHINA

BRIEF-Sino Biopharmaceutical posts 9-month ‍net profit attributable of RMB1.80​ bln

* Declared payment of a third quarterly dividend of HK2 cents per share for three months ended 30 Sept

BRIEF-Sino Biopharmaceutical posts HY revenue of about RMB7,482.86 mln

* HY revenue was approximately RMB7,482.86 million, an increase of approximately 10.6 percent

BRIEF-Sino Biopharmaceutical appoints Cheng Cheung Ling as executive director, vice chairlady

* Cheng Cheung Ling has been appointed as an executive director, vice chairlady of board Source text for Eikon: Further company coverage:

BRIEF-Sino Biopharmaceutical FY profit attributable HK$1.91 bln

* FY profit attributable to equity holders HK$1.91 billion, 7.6% higher

BRIEF-Sino Biopharmaceutical nine-month net profit HK$1.56 bln

* Declared payment of third quarterly dividend of HK1.5 cents per share for three months ended 30 september, 2016

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up